|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.97 EUR | -1.98% |
|
-1.00% | -20.59% |
| Apr. 25 | Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024 | CI |
| Apr. 23 | Transcript : Heidelberg Pharma AG - Special Call |
Heidelberg Pharma AG provided earnings guidance for the year 2023. For the year, the company expects sales revenue and other income to be between EUR 7 million and EUR 10 million. The half of the sales revenue to be related to partnerships with the ATAC technology and half of it to come from deferred income and potential milestone payments.
The main reason for the decrease compared to 2022 is the strong prior year effects of the Huadong partnership.
| 1st Jan change | Capi. | |
|---|---|---|
| -20.59% | 148M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
HEIDELBERG PHARMA AG 
